Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Combining Behavioral Treatment With Agonist Maintenance - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: October 27, 2008
Last verified: October 2008
The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition Intervention Phase
Cocaine-Related Disorders
Opioid-Related Disorders
Substance-Related Disorders
Drug: Buprenorphine
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior

Estimated Enrollment: 168
Study Start Date: September 1999
Arms Assigned Interventions
Experimental: 1
Therapeutic Contracting (TC)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
Experimental: 2
Cognitive Behavioral Coping Skills Therapy (CBT)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000311

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

Responsible Party: Richard S. Schottenfeld, MD, Yale University School of Medicine Identifier: NCT00000311     History of Changes
Other Study ID Numbers: NIDA-09413-1
Study First Received: September 20, 1999
Last Updated: October 27, 2008

Additional relevant MeSH terms:
Substance-Related Disorders
Opioid-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on May 25, 2017